- Home
- GALT vs MRCC Comparison
GALT vs MRCC Comparison
Compare GALT & MRCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- MRCC
- Stock Information
- Founded
- GALT 2000
- MRCC 2011
- Country
- GALT United States
- MRCC United States
- Employees
- GALT N/A
- MRCC N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- MRCC Investment Managers
- Sector
- GALT Health Care
- MRCC Finance
- Exchange
- GALT Nasdaq
- MRCC Nasdaq
- Market Cap
- GALT 147.8M
- MRCC 174.8M
- IPO Year
- GALT N/A
- MRCC 2012
- Fundamental
- Price
- GALT $2.12
- MRCC $8.21
- Analyst Decision
- GALT Strong Buy
- MRCC Strong Buy
- Analyst Count
- GALT 1
- MRCC 1
- Target Price
- GALT $11.00
- MRCC $9.00
- AVG Volume (30 Days)
- GALT 549.5K
- MRCC 71.5K
- Earning Date
- GALT 11-13-2024
- MRCC 11-12-2024
- Dividend Yield
- GALT N/A
- MRCC 12.15%
- EPS Growth
- GALT N/A
- MRCC 298.01
- EPS
- GALT N/A
- MRCC 0.60
- Revenue
- GALT N/A
- MRCC $62,007,000.00
- Revenue This Year
- GALT N/A
- MRCC N/A
- Revenue Next Year
- GALT N/A
- MRCC N/A
- P/E Ratio
- GALT N/A
- MRCC $13.71
- Revenue Growth
- GALT N/A
- MRCC N/A
- 52 Week Low
- GALT $1.56
- MRCC $6.77
- 52 Week High
- GALT $4.27
- MRCC $8.74
- Technical
- Relative Strength Index (RSI)
- GALT 39.78
- MRCC 42.18
- Support Level
- GALT $1.80
- MRCC $8.37
- Resistance Level
- GALT $2.36
- MRCC $8.66
- Average True Range (ATR)
- GALT 0.23
- MRCC 0.19
- MACD
- GALT -0.03
- MRCC -0.05
- Stochastic Oscillator
- GALT 26.89
- MRCC 1.85
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.